EMA refuses marketing authorisation application for Aduhelm
編集委員会 / Editorial Office
20/12/2021
![Research[1]](https://dementia-platform.jp/wp-content/uploads/fly-images/621/Research1-1280x0-c.png)
Alzheimer’s Disease International (ADI) has reported on its website that the European Medicines Agency (EMA) has rejected the application for approval of Aduhelm (drug name: adducanumab) as follows :
Source https://www.alzint.org/news-events/news/ema-refuses-marketing-authorization-application-for-aduhelm/
EMA refuses marketing authorisation application for Aduhelm
This follows the result of the negative vote trend by the Committee for Medicinal Products for Human Use (CHMP) at their oral explanation meeting in November.
*Please see the source for the text.
編集委員会 / Editorial Office
公益社団法人認知症の人と家族の会は1980年に結成された、認知症の人と家族・介護者が結成した民間の団体です。
See other articles from 編集委員会 / Editorial Office→
